Clearmind closes recruitment for repeat-dosing stage of alcohol disorder drug study
The Israel-based company has finished signing up participants for the placebo-controlled third stage of its early-to-mid-stage CMND-100 trial, but has released no data or timelines.
Clearmind Medicine said on 16 November 2026 that it has finished recruiting for Part C of the Phase I/IIa trial of CMND-100, its oral candidate for alcohol use disorder (AUD). The company describes the molecule as free of hallucinogenic effects and rooted in psychedelic research.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Clearmind Medicine Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.